Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, reported today its nine-month financial results ending September 30, 2019.

Read more